Analysts hold mixed views on Karyopharm Therapeutics due to its slower growth compared to the industry and increased loss per share estimates for next year, leading to a lower future valuation estimate.
Investors' belief in Karyopharm Therapeutics' poor revenue performance and underwhelming outlook contribute to its low P/S ratio. These conditions form a barrier for the share price.
QianmengYu :
I’ll wait, probably add a little after earning. Xpovio is like 1000 million to 1500 million worthy or cashflow, and debt plus lay off cost is like 400 million. Science now is huge negative values here, Just ridiculous.
$カリオファーム・セラピューティクス(KPTI.US)$Watching Karyopharm Therapeutics; Traders Circulate Analyst Comments Suggesting "With The MOR Takeover Interest, A Larger Cancer Company Could Also Be Interested In Acquiring KPTI For Selinexor"
I started with 50$ put it all on kyron$Karyopharm Therapeutics (KPTI.US)$ therapeutics now i have like a1.50$ is that possible
1
報告
QianmengYu :
I made 2000 dollar profit on this now I have 3000 unrealized loss. Cannot let scientists to run a company like this, too naive. Failed in sales, failed in cost control, failed in communication.
$カリオファーム・セラピューティクス(KPTI.US)$Presentation Of Updated Long-term Safety, Efficacy Data From A Pre-specified Exploratory Subgroup Analysis Of SIENDO Study In Patients With Advanced Or Recurrent TP53 Wild-type Endometrial Cancer
カリオファーム・セラピューティクスに関するコメント
Hmm?
Hope this means no dilution soon?
Update
Is time👀
まだコメントはありません